Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rotigotine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 12/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 10/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 7/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rotigotine SCHEMBL9405994 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL30200958 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL29354493 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL1088585 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL2597402 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL30730591 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL15970012 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL29483747 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL2597403 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL14697993 | 0.94 | DRD2 (0.89) | DRD2DRD3DRD4DRD1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9533 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122079971-A | Preparation method of rotigotine degradation impurity | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026102000-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA 1 DEFICIENCY | VOYAGER THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| CN-122031353-A | Rotigotine-loaded triboelectric microneedle patch and preparation method and application thereof | 浙江大学 | 2026-05-15 | — | — | CN | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4727627-A1 | AEROSOL-GENERATING DEVICE WITH IMPROVED AIRFLOW | Alexza Pharmaceuticals, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4727931-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE SECONDARY AMINES AND THEIR USE AS INTERMEDIATES | INKE, S.A. (ES) | 2026-04-22 | — | — | EP | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-1232152-A1 | IMPROVED PROCESS FOR PREPARING NITROGEN-SUBSTITUTED AMINOTETRALINS | Aderis Pharmaceuticals, Inc. (US) | 2002-08-21 | — | — | EP | claimed |
| US-6372920-B1 | ALKYLATING 2-AMINOTETRALIN IN PRESENCE OF BASE SELECTED FROM ALKALI METAL CARBONATES AND BICARBONATES, WHEREIN AMOUNT OF BASE IS LESS THAN ABOUT 1.9-FOLD MOLAR EXCESS WITH RESPECT TO AMOUNT OF 2-AMINOTETRALIN | ADERIS PHARMACEUTICALS, INC. | 2002-04-16 | — | — | US | claimed |
| EP-1033978-B1 | TRANSDERMAL THERAPEUTIC SYSTEM WHICH CONTAINS A D2 AGONIST AND WHICH IS PROVIDED FOR TREATING PARKINSONISM, AND A METHOD FOR THE PRODUCTION THEREOF | LOHMANN THERAPIE SYST LTS (DE) | 2001-12-19 | — | — | EP | claimed |
| WO-2001038321-A1 | IMPROVED PROCESS FOR PREPARING NITROGEN-SUBSTITUTED AMINOTETRALINS | ADERIS PHARMACEUTICALS, INC. (US) | 2001-05-31 | — | — | WO | claimed |
| EP-1067916-A2 | METHOD FOR PRODUCING TRANSDERMAL THERAPEUTIC SYSTEMS BY USING BASIC ALKALI METAL SALTS FOR CONVERTING ACTIVE AGENT SALTS INTO FREE BASES | LTS Lohmann Therapie-Systeme AG (DE) | 2001-01-17 | — | — | EP | claimed |
| EP-1033978-A1 | TRANSDERMAL THERAPEUTIC SYSTEM WHICH CONTAINS A D2 AGONIST AND WHICH IS PROVIDED FOR TREATING PARKINSONISM, AND A METHOD FOR THE PRODUCTION THEREOF | LTS Lohmann Therapie-Systeme AG (DE) | 2000-09-13 | — | — | EP | claimed |
| WO-1999049852-A1 | TRANSDERMAL THERAPEUTIC SYSTEM WHICH CONTAINS A D2 AGONIST AND WHICH IS PROVIDED FOR TREATING PARKINSONISM, AND A METHOD FOR THE PRODUCTION THEREOF | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 1999-10-07 | — | — | WO | claimed |
| WO-1999049844-A2 | METHOD FOR PRODUCING TRANSDERMAL THERAPEUTIC SYSTEMS BY USING BASIC ALKALI METAL SALTS FOR CONVERTING ACTIVE AGENT SALTS INTO FREE BASES | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 1999-10-07 | — | — | WO | claimed |
| EP-0230629-A2 | 2-Propylamino-tetralin derivatives for reducing intraocular pressure | Whitby Research Incorporated (US) | 1987-08-05 | — | — | EP | claimed |
| US-4657925-A | Method and compositions for reducing the intraocular pressure of mammals | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1987-04-14 | — | — | US | claimed |